Our Team
We're HiringFor decades, mental health treatment options have excluded the very promising segment of psychedelic-assisted therapies. Just as psychiatrists, psychologists, and other researchers were making incredible headway on their studies of compounds like MDMA, psilocybin, and Ayahuasca (among others) in the 1990’s, the U.S. government criminalized these substances, blocking research across the globe. Now, in 2024, that is about to change.
Efficacy rates for treating PTSD with MDMA-assisted therapy exceed 87% in clinical trials! In August of 2024, we anticipate the legalization of MDMA for the treatment of PTSD in the United States. A sea change is upon us. The exploration and availability of other psychedelic-assisted treatments should follow. The extraordinary promise of these therapeutic modalities cannot be overlooked, as the efficacy and impact of these treatments are setting a new bar for effective, safe, and enduring mental health treatments. Let’s accelerate the spread of traumatic recovery, grounded in science.
Protea Foundation supports diversity, equity and inclusion:
As a science-driven foundation, Protea Foundation acknowledges the extraordinary miracle that precedes this moment: you’re here, and we’re so grateful for it. Gratitude leads our mission. Thank you for being exactly who you are, exactly as you are, and tuned in to our mission. Your voice is welcome as we expand awareness of what the world might be like with absolute respect and tolerance for one another despite oppressive structures that persist through human existence.
We are diverse. We aspire always to be equitable and inclusive. If we lack awareness, please let us know.
John Drake
Partner
Jane Caverner
Partner
Cristina Pearse
CEO & Founder
Dave Brow
Partner
Janet Stall
Partner
Brent Chapman
Partner
Nicole Waller
Partner
Stephen Brown
Partner